Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

MYSTERIOUS: Sandoz - What They Never Told You

Novo Nordisk is losing Canadian patent protection on a blockbuster drug after not paying a small fee

“I’m sure someone’s lost their job,” said the CEO of Sandoz, which has now filed to launch a generic GLP-1 drug in Canada next year.

Fortune

Americans would suffer most if Trump imposes pharma tariffs, sector warns

Industry says levies would hit supply chains, making medicines potentially unaffordable for some US patients

The Guardian - UK

MS patients suffer side-effects after NHS England switches to cheaper drug

Scores of people experience complications after change from Tysabri to Tyruko as part of NHS drive to save money

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

UK grocery inflation picks up to 2.3%; unemployment rises while regular wage growth slows – as it happened

Consumers started their Christmas shopping early, Kantar says; UK jobless rate rises to 4.3% while wage growth excluding bonuses is at a two-year low

The Guardian - UK

3 Pharma Stocks With Potential to Outperform Pfizer Inc. (PFE) in October

Pfizer (PFE) is grappling with financial difficulties and declining performance. Yet, with growing pharmaceutical demand and industry advancements, robust pharma stocks Zoetis (ZTS), Horizon Therapeutics (HZNP), and Novartis (NVS) appear as more promising buys this month. Read on.

StockNews.com

3 Pharma Stocks Surpassing Johnson & Johnson (JNJ)

The pharmaceutical sector is anticipated to thrive as demand grows and technology advances. While Johnson & Johnson (JNJ) receives much attention from investors, I believe Horizon Therapeutics Public Limited (HZNP), Dr. Reddy’s Laboratories (RDY), and Novartis (NVS) are better investments right now. Read on.

StockNews.com

Top 3 Pharma Stocks to Boost Your Portfolio

As the global population ages and faces the increasing toll of chronic diseases, the pharmaceutical industry is expected to step up to meet people’s healthcare needs. Against this backdrop, pharma companies like Novo Nordisk (NVO), AbbVie (ABBV), and Novartis (NVS) could boost your portfolio. Read on….

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

3 Pharma Stocks With Promising Pipelines

The pharma industry is anticipated to stay buoyed in the years to come with consistent medical breakthroughs and rising need to serve an aging population. Therefore, pharma stocks Johnson & Johnson (JNJ), Novartis AG (NVS), and Dr. Reddy's Laboratories (RDY), which possess promising pipelines, could be wise portfolio additions now.…

StockNews.com

2 Must-Have Pharma Stocks to Buy in August, 1 to Sell

The pharmaceutical industry is poised to thrive amid increasing global healthcare demand. Hence, two quality pharma stocks, Johnson & Johnson (JNJ) and Novartis AG (NVS), could be solid portfolio additions. However, avoiding fundamentally weak stock SNDL Inc. (SNDL) could be a wise choice. Read more.

StockNews.com

3 Pharmaceutical Stocks to Watch

The pharmaceutical industry is anticipated to grow due to rising chronic diseases and an aging population. Given the industry's strong long-term prospects, quality stocks Novo Nordisk (NVO), Novartis (NVS), and Bristol-Myers Squibb (BMY) could be worth adding to your watchlist. Continue reading….

StockNews.com

4 Best Pharma Stocks to Buy for the Long Haul

With the persistent rise in lifestyle diseases, the pharmaceutical industry is well poised for strong growth in the long term. Also, with the Fed likely to keep increasing the interest rates, the economy is likely to enter a recession, making pharma stocks attractive investment options. Therefore, investors could look to…

StockNews.com

3 Hot Dividend Stocks to Buy Now and Hold Forever

Due to a barrage of strong macroeconomic data, the Federal Reserve has expressed the need to keep interest rates elevated. This is expected to keep the market volatile. Amid this backdrop, it might be wise to buy fundamentally strong dividend stocks Johnson & Johnson (JNJ), Novartis (NVS), and ARC Document…

StockNews.com

The 5 Safest Stocks You Can Buy in 2023

The stock market might remain volatile in the near term amid the still-alarmingly high inflation and the anticipated continuation of rate hikes. Therefore, fundamentally strong Eli Lilly (LLY), Novartis (NVS), Comcast (CMCSA), HCA Healthcare (HCA), and Myers Industries (MYE), which pay steady dividends, might be safe buys now. Read more.

StockNews.com

$1,000 Invested in These 3 Stocks Could Make You Richer in 2023

Hot economic data and rekindled price pressures are expected to keep the stock market highly volatile, with the Fed minutes signaling continued rate hikes in upcoming meetings. Amid this backdrop, investing $1,000 in fundamentally sound and dividend-paying stocks Walmart (WMT), Novartis (NVS), and Albertsons (ACI) could make you richer this…

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

2 Stable Stocks to Add to Your Portfolio in 2023

Amid soaring concerns over an impending Fed-induced recession, the stock market could remain volatile in the near future. Against this backdrop, investors could add stable stocks Johnson & Johnson (JNJ) and Novartis (NVS) to their portfolios in 2023 to garner good returns. Read on….

StockNews.com

The 3 Best Pharma Stocks to Buy for Big Gains in 2023

The pharma industry witnessed solid growth amid the pandemic. Moreover, with surging demand, rising investments in research and development, and increasing e-pharmacy channels, the industry is well-positioned for significant growth over the coming years. Therefore, investors could consider buying fundamentally sound pharma stocks Johnson & Johnson (JNJ), AbbVie (ABBV), and…

StockNews.com

3 Stable Stocks That Could Help Pay Your Bills in 2023

Despite eased inflation, the robust jobs report raised the prospect of progressive rate hikes. With anxiety escalating about the possibility of a Fed-induced recession, the market volatility is expected to remain elevated in the near future. Hence, investors could consider fundamentally sound and stable stocks Novartis (NVS), Descartes Systems (DSGX),…

StockNews.com

2 Stable Stocks You Can Buy Now for Under $100

Despite the recent positive macro data, the recession possibility remains as the Federal Reserve is expected to keep hiking rates until its target is met. So, dividend-paying healthcare stocks Novartis (NVS) and Takeda Pharmaceutical (TAK) could be stable investment options to safeguard your portfolios. These stocks are trading under $100.…

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

3 Reliable Stocks That Could Help You Make Money in 2023

The stock market witnessed a decent rally in January, with cooling inflationary pressures reducing recession fears. However, the Fed’s attempts to bring inflation down to its 2% target could hurt economic growth. Hence, it could be wise to invest in shares of Johnson & Johnson (JNJ), Novartis (NVS), and LCNB…

StockNews.com

3 Stocks It Is Time to Buy Now

Although headline inflation has slowed, the Fed will likely keep raising interest rates to attain its 2% target. However, a potential slowdown in monetary policy tightening is opening the path for quality stocks to recover. Therefore, investors should consider buying fundamentally sound stocks Merck & Co. (MRK), Novartis (NVS), and…

StockNews.com

3 Safe Stocks to Buy in an Unpredictable Market

The Fed’s intention to continue raising interest rates, disappointing economic data, and a weak earnings season could keep the stock market highly volatile. Hence, investing in quality stocks Microsoft (MSFT), Johnson (JNJ), and Novartis (NVS) could be safe. Continue reading.

Benzinga

Benzinga Before The Bell: Twitter Whistleblower Peiter Zatko To Depose Before Senate Panel, GameStop To Boost Employee Compensation To Drive Growth, California Proposes Total Ban On New Gasoline Car Sales By 2035 And Other Top Financial Stories Thursday, August 25

Reuters Stuck By Chip Shortage, Stellantis Halts Production In Sochaux Plant

Tribune News Service

‘Please pay attention’: Scientist flagged heart-pill toxins early on

A scientist at a China-based company that makes crucial ingredients for generic drugs warned a year before the start of a global recall that some blood-pressure pills could become tainted with potentially cancer-causing chemicals, according to court documents.

Benzinga

Novartis Posts Higher Q1 Earnings, Sales On Strong Sandoz, Entresto; Backs 2022 Outlook

Novartis AG (NYSE:NVS) has reported a core EPS of $1.46 in Q1 FY22 compared to $1.38 a year ago, beating the consensus of $1.44. Net income reached $2.2 billion, an increase of 8% or 15% at constant currency rates, mainly driven by higher operating income, partly offset by the loss of Roche Holding (OTC:RHHBY) income.…

Benzinga

Novartis Expects FY22 Sales, Profit Growth; Sandoz Review Continues

Novartis AG (NYSE: NVS) reported a Q4 net income of $16.31 billion, up from $2.1 billion the previous year,

1 2

People

Mangeet Kaur BounsMangeet

595 stories

Sristi Suman Jayaswal

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Office for National Statistics

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.